Key facts
- Notable investors include Caltech, Scranton Enterprises.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Serabiotics
- ·The full record, as it builds
Funding rounds
No funding rounds for Serabiotics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Serabiotics
Developer of an advanced plasma technology designed for the development of human and veterinarian plasma- and blood-derived products for non-therapeutic applications. The company specializes in embryo culture technology, cell therapy, plasma fractionation, cell culture supplements, and in vitro assays, enabling pharmaceutical and biotech partners to utilize cell biology, assisted reproduction, and drug development.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2017
- Website
- serabiotics.com/
- Ownership
- Privately Held (backing)
Serabiotics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Serabiotics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Serabiotics in its N-PORT filings yet. We sweep new filings monthly.